Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from Harvard University describe findings in cancer gene therapy
June 30th, 2009
Current study results from the report, 'Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells,' have been published. "Genetically engineered oncolytic herpes simplex virus-1 (HSV-1) vectors selectively replicate in tumor cells causing direct killing whereas sparing normal cells. One clinical limitation of using oncolytic HSV vectors is their attenuated growth," scientists writing in the journal Cancer Gene Therapy report. "We hypothesized that the appropriately chosen chemotherapeutic agent combined with an oncolytic HSV could be an effective means to promote augmented prostate cancer cell killing both in vitro...
Source: Cancer Weekly (2009-06-30)
|
